A Phase 1 Study to Evaluate the Safety of OBP-301, Telomelysin in Combination With Radiation Therapy in Patients With Esophageal Cancer Not Applicable for Standard Therapy
Phase of Trial: Phase I
Latest Information Update: 14 Jul 2017
At a glance
- Drugs Telomelysin (Primary)
- Indications Oesophageal cancer
- Focus Adverse reactions
- Sponsors Oncolys BioPharma
- 07 Jul 2017 According to an Oncolys BioPharma media release, this trial will enroll patients in two sites, Okayama University Hospital and National Cancer Centre Hospital East in Chiba Prefecture.
- 07 Jul 2017 Status changed from not yet recruiting to recruiting, according to an Oncolys BioPharma media release.
- 07 Jul 2017 According to an Oncolys BioPharma media release, first patient has been enrolled.